Motherhood
New partnership could help patients with postpartum depression

The newly launched MamaLift programme provides postpartum depression support for expecting and new mothers.
Curio Digital Therapeutics and Axia Women’s Health are collaborating to support women diagnosed with postpartum depression and those at risk. Through the launch of the MamaLift program, women can access a webpage that provides them with personalised trackers and tools to help manage symptoms of depression and anxiety.
The MamaLift programme is a five week programme that includes short term, web-based modules focused on developing skills to help manage symptoms of anxiety and depression, promoting social support and relationship quality, and encouraging help-seeking behaviour.

Credits: Mamalift.curiodigitaldx.com
Dr. Gerard Reilly, director of the Clinical Research Division at Axia Women’s Health, said “We believe addressing and caring for women’s mental well-being is a critical part of improving women’s overall health. We’re proud to partner with Curio to connect our patients to this innovative technology that helps to make mental healthcare more accessible and more convenient for our pregnant and postpartum patients.”
MamaLift was developed specifically for women during pregnancy and postpartum and uses clinical data. While it is a general wellness device, MamaLift has been tested in randomised, controlled clinical trials.
The programme provides science-based content and personalised self-help tools and trackers through clinical trials that included more than 16000 patients.

Credits: mamalift.curiodigitaltx.com
“The MamaLift programme was developed to help women through the challenging time following delivery. Our partnership with Axia will bring MamaLift to more women, helping them and advancing our mission of improving women’s health,” said Shailja Dixit, founder of Curio Digital Therapeutics.
Curio aims to “bring innovative and evidence-based digital therapeutics products to market that support women and help to improve their health,” she added.
Postpartum depression is a common problem that affects more than one in every ten women within a year of giving birth. The cause of this type of depression are still not completely clear.
According to Curio “technology is a critical must-have for women’s health, making it easy to scale mental and behavioural health support for women and deliver it to them on-demand, on their schedule.
“There is a worsening shortage of therapists and other mental health professionals during a time when there is increased stress and anxiety for women.
“Digitised mental and behavioural health support can help fill this void, as well as to connect women and triage them to healthcare professionals when they need additional support.”
Fertility
Health Secretary announces inquiry into Leeds maternity services

An independent inquiry will be launched into Leeds maternity services following a parent-led campaign over care failures stretching back 14 years.
Health secretary Wes Streeting said he was deeply concerned about problems at Leeds Teaching Hospitals NHS Trust, calling it “a real outlier” for perinatal mortality — deaths around the time of birth — compared with other hospitals nationally.
The announcement follows maternity services at the trust being rated “inadequate” after an unannounced Care Quality Commission inspection in December and January.
A subsequent NHS England report raised “significant” concerns about safety and quality of care.
After meeting affected parents in the city, Streeting said the trust — which runs maternity units at Leeds General Infirmary and St James’s Hospital — required scrutiny similar to the ongoing Nottingham maternity inquiry.
“I’ve decided that we need a Nottingham-style independent inquiry into what’s going on with maternity and neonatal services in Leeds,” he said.
“I think we need clear answers, accountability and improvement… I do think we need that independent look, not just for what’s happening now but stretching back to historic cases as well.”
The Nottingham review — the largest maternity inquiry of its kind — has examined hundreds of baby deaths and injuries at Nottingham University Hospitals.
It has led to the NHS paying out tens of millions of pounds for claims dating back to 2006 and prompted a police investigation, with findings expected next year.
Dozens of baby deaths in Leeds in recent years are thought to have been preventable.
Families affected by avoidable deaths of babies or mothers have long campaigned for an independent investigation.
Streeting has already commissioned a national review of NHS maternity services but said Leeds was an “exceptional case” that warranted its own inquiry.
“I don’t want to drown the NHS across the country in a whole series of local reviews into what I think is a national problem,” he said.
“But I have been persuaded, having been to Leeds recently to listen to families and look at the data.
“Given the challenges still evident — not least from the most recent Care Quality Commission inspection — and Leeds’s scale as one of the largest teaching hospitals in Europe, I think all of those things point to Leeds as an exceptional case for this kind of inquiry.”
He said details of the inquiry’s scope would be announced soon.
“I’ll proceed without fear or favour. If there are individuals who need to be held to account, I will ensure accountability.
“Where systemic improvements are needed, I will make sure they happen, and that’s why I believe this specific investigation is necessary.”
Campaigners welcomed the decision, describing the current system as “rotten”.
Fiona Wisner-Ramm and Daniel Ramm, whose daughter Aliona died 27 minutes after birth in 2020 following what an inquest described as “gross failures” in care, have been among those leading the campaign.
“This means that Leeds Teaching Hospitals NHS Trust will now be properly investigated, allowing for meaningful changes to its culture and practices,” they said in a statement.
“We hope that this inquiry will finally break the cycle of repeated errors and inadequate leadership, helping to prevent further deaths and injuries to mothers and babies.”
News
Protective immune cells in breastfeeding women guard against breast cancer, research finds

Women who breastfeed develop protective immune cells that help guard against breast cancer, with effects lasting for more than 30 years, new research shows.
The study found that specialised T-cells — immune cells that fight disease — remain in breast tissue long after pregnancy and provide lasting protection, particularly against triple-negative breast cancer, one of the most aggressive forms.
Observations dating back to the 18th century, when physicians noticed nuns had some of the highest rates of breast cancer, first hinted that childbearing and breastfeeding could protect against the disease.
Modern research has confirmed this link, though the biological explanation was unclear.
Professor Sherene Loi is senior author and clinician scientist at the Peter MacCallum Cancer Centre.
The researcher said: “The key take-home messages are that pregnancy and breastfeeding will leave behind long-lived protective immune cells in the breast and the body, and these cells help to reduce risk and improve defence against breast cancer, particularly triple-negative breast cancer, but potentially other cancers as well as disease.”
Researchers from the Peter MacCallum Cancer Centre in Melbourne studied non-cancerous breast tissue from more than 260 women who had undergone breast reduction or preventive surgery.
They found that women who had given birth had more specialised immune cells called CD8⁺ T-cells — part of the adaptive immune system that targets specific threats, including cancer.
The team then tested whether these cells directly provided protection.
In mice, cancer cells implanted into breast tissue grew less in those that had pups and breastfed compared with those that had not. When the researchers removed the T-cells from the nursing mice, the protective effect disappeared.
The researchers also analysed data from more than 1,000 breast cancer patients diagnosed after childbirth with available breastfeeding records.
Women who had breastfed had better outcomes from triple-negative breast cancer than those who had not. Their tumours also contained more immune cells, suggesting ongoing immune activity against the cancer.
The study provides an explanation for why breastfeeding appears protective, and the findings could help inform new strategies for women unable to have children or breastfeed.
Understanding the underlying biology may aid development of vaccines or therapies that mimic this natural defence.
Professor Loi said: “The effects are really quite small for every individual, but population-wide the effects are large.”
She stressed that breastfeeding does not guarantee protection against breast cancer, noting it is “not a 100 per cent guarantee that they won’t get breast cancer.”
The study also explored why some breast cancers contain high numbers of specialised immune cells while others do not.
Patients with more of these cells generally had better outcomes, particularly with triple-negative breast cancer.
Professor Loi explained that T-cells react not only to viruses or bacteria but also to cancer, describing this response as “one of our very modern therapeutic weapons against cancer.”
Associate Professor Wendy Ingman from the University of Adelaide’s Medical School said longer breastfeeding duration provided greater benefits.
Each year of breastfeeding is linked to a 4 per cent lifetime reduction in the mother’s breast cancer risk.
“This study shows that having babies and breastfeeding causes long-lasting changes in immune cells that could help protect the breast from cancer,” Ingman said.
“I’m hopeful that this type of research will lead to new approaches to reduce women’s breast cancer risk.”
Pregnancy
Psilocybin may make postpartum depression worse, study finds

Psilocybin may heighten anxiety and depression in new mothers rather than help treat postpartum mental health conditions, research suggests.
Scientists found that giving mouse mothers the psychedelic drug – the active compound in magic mushrooms – increased anxiety and depressive-like behaviour linked to perinatal mood disorders, which are mental health conditions that can develop during or after pregnancy.
The results challenge assumptions about psilocybin’s therapeutic use, indicating it may not be suitable for all patient groups.
David E. Olson, director of the IPN and professor of chemistry, biochemistry and molecular medicine at UC Davis, said: “The IPN has done a lot of work demonstrating that a single dose of a psychedelic can lead to long-lasting, beneficial effects.
“But it’s a little more nuanced than that in terms of who can really benefit and who might be at risk.
“There are different patient populations.”
Researchers at the University of California, Davis Institute for Psychedelics and Neurotherapeutics tested the drug in a mouse model of postpartum depression.
In this model, mothers could escape into a separate cage, mimicking the infant avoidance seen in human postpartum depression.
The negative effects persisted for two weeks after a single dose.
More concerning, pups raised by psilocybin-treated mothers also showed anxiety and depression-like symptoms into adulthood, suggesting harmful effects were passed on through lactation and altered brain development.
Co-author Danielle Stolzenberg, associate professor of psychology at UC Davis, said: “One of the things that’s discussed consistently in the clinical literature is that mums often feel like they have trouble bonding with their infants when they’re experiencing depressive symptoms.
“The mouse mums in the social stress paradigm spend significantly more time in the cage without the pups.
“They will often run back and forth to check on them but tend to actively avoid their infants for long periods of time.”
The team had expected positive results given psilocybin’s reported benefits for other mental health conditions.
“Psilocybin was of such interest for us because it’s been demonstrated to be useful across a whole host of mental disorders, including addressing anxiety and depression,” said first author Cassandra Hatzipantelis, a postdoctoral fellow at the IPN.
“We thought it could have the ability to address things that go wrong in postpartum depression, like the parent-infant connection.”
Instead, the mouse mothers continued to avoid their offspring and showed persistent symptoms even after separation.
Psilocybin-treated mice were also at higher risk of behavioural impairments and depressive-like symptoms.
Nine weeks after weaning, both male and female offspring showed heightened anxiety and depression compared with control groups.
Their brains also contained traces of psilocin, the metabolite produced when the body processes psilocybin.
“We now know that even low doses of exposure can impact offspring for long periods of time,” Stolzenberg said.
“These could be really important therapeutics, but we also realise they have limitations, and we have to conduct rigorous science to understand what those limitations are,” Olson added.
News4 days agoDozens of women report suffering painful burns after using Always sanitary towels
Opinion3 weeks agoFDA plans to revise black box warning on menopause hormone therapies
Hormonal health2 weeks agoAI-powered women’s health companion Nexus launches in UK
Insight1 week agoWomen’s health innovations recognised in TIME’s Best Inventions 2025
News3 weeks agoScientists turn human skin cells into eggs in IVF breakthrough
News3 weeks agoDaily pill could delay menopause ‘by years,’ study finds
News3 weeks agoAncient herb to modern must-have: Why ashwagandha is capturing UK women’s attention
News2 weeks agoMenstrual cycle affects women’s reaction time, study finds














5 Comments